1,099
-0.45%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Myungmoon Pharm Co
Its shares trade on KRX under the ticker 017180.KS. It has been listed since 10 July 2008. In the fiscal year to 31 December 2025, it reported revenue of ₩195.25bn and net income of ₩1.90bn. At that date it held total assets of ₩272.46bn and shareholders' equity of ₩98.74bn.
MYUNGMOON Pharm Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-07-10. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The firm is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jul 2008
- Website
- mmpharm.co.kr ↗
Leadership
Pay as last reported
- Seok Min WooPresident, Chief Executive Officer, Director, since 2016
- Cheol Han BaeCo-Chief Executive Officer, Director
- Chun Sik ParkCo-Chief Executive Officer, Director
- Jae Geon HahVice President, Managing Director
- Sang Jin BaeInternal Auditor
- Gi Beom KimAssistant Managing Director
- Wu Yeong LeeAssistant Managing Director
- Yeong Mi LeeAssistant Managing Director
- Chang Hun ShinAssistant Managing Director
- Yong Gyeong SungAssistant Managing Director
- Yong Jin JungNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Myungmoon Pharm's diverse product portfolio includes ethical and OTC drugs for various medical needs.
- The company's headquarters in Hwaseong, Gyeonggi-Do, supports efficient pharmaceutical manufacturing operations.
- Myungmoon Pharm's merger with its subsidiary in 2012 strengthened its operational capabilities.
Weaknesses
- The company's reliance on pharmaceutical manufacturing limits its market diversification opportunities.
- Myungmoon Pharm's business is primarily focused on domestic Korean market without global expansion.
- The firm's involvement in golf course operations does not align with its core pharmaceutical business.
Opportunities
- Growing demand for ethical drugs in Korea presents expansion potential for Myungmoon Pharm.
- Increasing OTC drug market in South Korea offers new revenue streams for the company.
- Potential for partnerships with international pharmaceutical firms to enhance product offerings.
Threats
- Competition from established Korean pharmaceutical companies in the domestic market.
- Regulatory changes in the Korean pharmaceutical industry could impact production.
- Economic downturns may reduce consumer spending on non-essential OTC drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.